Table 2.

Risk for breast cancer.

Analysis time	Antibody	Subtype	Person-years	No. observed	No. expected	SIR (95% CI)	p-value
Overall risk	All	limited	26624	42	57.6	0.73 (0.53–0.99)	0.039
		diffuse	11062	28	20.3	1.38 (0.91–1.99)	0.123
	Cenp	limited	11857	18	29.9	0.60 (0.36–0.95)	0.027
		diffuse	754	3	1.6	1.84 (0.38–5.39)	0.45
	Topo	limited	4035	8	8.2	0.97 (0.42–1.92)	0.99
		diffuse	3134	5	5.3	0.95 (0.31–2.21)	0.99
	Pol III	limited	962	1	1.9	0.52 (0.01–2.91)	0.86
		diffuse	2509	16	5.2	3.06 (1.75–4.98)	<0.001**
	CTP-Negative	limited	4065	12	7.2	1.66 (0.86–2.89)	0.130
		diffuse	1709	1	3	0.33 (0.01–1.83)	0.39
± 3 years	All	limited	7935	15	12.8	1.17 (0.66–1.94)	0.60
		diffuse	5210	17	8.3	2.06 (1.20–3.29)	0.010
	Cenp	limited	3003	4	5.4	0.75 (0.20–1.91)	0.76
		diffuse	212	0	0.4	0.00 (0.00–9.33)	0.99
	Topo	limited	1353	1	2.1	0.48 (0.01–2.69)	0.78
		diffuse	1393	3	2	1.51 (0.31–4.41)	0.64
	Pol III	limited	305	0	0.6	0.00 (0.00–6.66)	0.99
		diffuse	1209	12	2.3	5.14 (2.66–8.98)	<0.001**
	CTP-Negative	limited	1335	8	1.8	4.44 (1.92–8.74)	0.001**
		diffuse	808	1	1.1	0.87 (0.02–4.86)	0.99

^**Statistically significant p-value after adjustment for multiple (10) comparisons per analysis